Patent ID: 6677368
Filing Date: 2004-01-13
Classification: A61P,C07D

Abstract:
A compound of the formula I: wherein:R1 is aryl, optionally substituted by one or more substituent selected from the group consisting of halogen, â€”OR6, â€”COR6, â€”COOR6, OCOR6, â€”CONR6R7, â€”R6NCOR7, â€”NR6R7, â€”CN, â€”NO2, â€”CX3, â€”SR6, SOR6, â€”SO2R6, â€”SO2OR6, â€”SO2NR6R7, â€”R6NSO2R7, perfluoroalkyl, lower alkyl, lower alkyl further substituted by one or more of R2, lower alkenyl, lower alkenyl further substituted by one or more of R2, lower alkynyl, lower alkynyl further substituted by one or more of R2, cycloalkyl, cycloalkyl further substituted by one or more of R2, a heterocyclic ring, a heterocyclic ring further substituted by one or more of R2, aryl and aryl further substituted by one or more of R2; R2 is selected from the group consisting of hydrogen, halogen, â€”OR6, â€”CONR6R7, â€”R6NCOR7, â€”NR6R7, â€”CX3, â€”SR6, SOR6, â€”SO2OR6, â€”SO2NR6R7, lower alkyl and aryl; R3 is selected from the group consisting of hydrogen, halogen, â€”OR6, â€”COR6, â€”OCOR6, â€”CONR6R7, â€”NR6R7, â€”CN, â€”NO2, and lower alkyl; wherein said lower alkyl is further substituted by â€”CONR6R7, NR6R7, â€”SO2R6, â€”R6NSO2R, or SO2NR6R7; R4 is selected from the group consisting of hydrogen, halogen, â€”OR6, â€”COR6, â€”OCOR6, â€”CONR6R7, â€”NR6R7, â€”CN, â€”NO2, and lower alkyl, wherein said lower alkyl is further substituted by â€”CONR6R7, NR6R7, â€”SO2R6, â€”R6NSO2R, or SO2NR6R7; R5 is selected from the group consisting of hydrogen, halogen, â€”OR6, â€”COR6, â€”OCOR6, â€”CONR6R7, â€”NR6R7, â€”CN, â€”NO2, and lower alkyl; provided that no more than one of R3, R4, or R5 is hydrogen; R6 and R7 are independently selected from the group consisting of hydrogen, â€”CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; wherein lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, the heteocyclic ring or aryl may be further substituted by one or more of (i) â€”NR12R13, (ii) hydroxy, (iii) halo, (iv) a heterocyclic ring, (v) lower alkyl, (vi) â€”C(O)â€”NR12R13, (vii) â€”OR12, (viii) â€”SO2R12R13, or (ix) â€”COR6; wherein said heterocyclic ring (iv) may be further substituted by one or more of lower alkyl, â€”COR12, â€”NR12COR13, halogen, â€”OR12, CX3, â€”C(O)NR12R13, â€”SO2R12R13, or â€”SO2NR12R13, or R6 and R7 may be linked together to form a 4, 5- or 6-membered ring, optionally containing a hetero atom selected from the group consisting of N, O, S and SO2, which may be further substituted by â€”CONR12R13, lower alkyl, hydroxy, â€”(CH2)nâ€”NR12R13, â€”(CH2)n-heterocycle, â€”(CH2)nâ€”C(O)â€”NR12R13, â€”(CH2)nSO2R12R13, or â€”(CH2)nNSO2R12R13, wherein said heterocycle may be further substituted by halo, lower alkyl, â€”COR12, hydroxy, â€”C(O)â€”NR12R13, â€”OR12, â€”SO2R12R13, or â€”SO2NR12R13; X is fluorine, chlorine, bromine or iodine; R12 is selected from the group consisting of hydrogen, â€”CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, â€”(CH2)n-cycloalkyl, â€”(CH2)n-heterocycle, and aryl; R13 is selected from the group consisting of hydrogen, â€”CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, â€”(CH2)n-cycloalkyl, â€”(CH2)n-heterocycle, and aryl; or R12 and R13 may be linked together to form a 4-, 5- or 6-membered ring optionally containing one or more hetero atoms selected from the group consisting of O, N, S, SO and SO2, which may contain 1 or 2 double bonds; or a pharmaceutically acceptable salt thereof.